Beyond the Amanita trip: Lived experience in online communities.

Abstract

Background/aim: Interest in psychoactive Amanita fungi is rising, yet literature on their contemporary use remains limited. Unlike psilocybin-containing fungi, Amanita species are pharmacologically distinct and inconsistently regulated. Recent toxicological incidents have intensified safety concerns but lived experience perspectives remain underexplored. This study presents a qualitative analysis of online forum data, examining motives, modalities, and their intersections across themes with relevance for addiction treatment and public health.

Population/setting: Data were drawn from publicly accessible online communities focused on psychoactive substance use: Shroomery, Amanita Research Forum, and Reddit. These platforms host a diverse user base engaging with psychoactive Amanita and related species across therapeutic, spiritual, recreational, and harm-reduction contexts.

Methods: Data collection (2020–2024) followed constructivist grounded theory principles, comprising 1,273 posts from 115 threads (592 users). Data were analysed using qualitative content analysis, followed by two iterative waves of reflexive thematic analysis involving open and axial coding to develop and refine themes. An independent coder assessed a 10% subsample; intraclass correlation coefficient = 0.92. A reflexive journal was maintained throughout.

Results/findings: Four motive themes emerged: auto-gnosis (self-knowledge, including psychospiritual exploration and self-medication), self-enhancement (cognitive and recreational use), psychonautics (altered state experimentation), and accessibility-driven use. Modalities varied across species, administration forms, and temporal phases (before, during, and after). Coadministration was common. Intersectional findings showed how forum culture and individual context shaped experience and practice. Reported pharmacological concerns included reverse tolerance, cumulative toxicity, and interactions with γ-aminobutyric acid (GABA) agonists.

Conclusion: Contemporary Amanita use reflects a complex interplay of motives, cultural context, and pharmacological risks. The diversity of experiences underscores the need for nuanced, evidence-informed engagement by research and clinicians. Self-reported pharmacological concerns warrant further investigation, and future qualitative research should extend beyond online data sources to deepen understanding.

Translational impact/implications for future practice: Clinicians should anticipate complex and variable Amanita-related presentations and address any unmet therapeutic need. Findings can inform clinical training on recognition, brief intervention, and referral pathways. Public health efforts can utilise online forums as sites of peer knowledge exchange for surveillance and targeted harm-reduction outreach.